In May 2021, NICE indicated its intention to review and update existing guidance for TA379; Nintedanib for treating idiopathic pulmonary fibrosis and TA504; Pirfenidone for treating idiopathic pulmonary fibrosis to consider the patient population not currently recommended to receive treatment in the existing guidance. Since then, NICE have been liaising with the companies to ascertain the most appropriate approach to the review.
I am writing to inform you that following discussions with Boehringer Ingelheim, NICE are to undertake a partial review of NICE Technology Appraisal Guidance No.379, Nintedanib for treating idiopathic pulmonary fibrosis. NICE will review the population for those which nintedanib currently isn’t recommended (those with FVC > 80%). The draft timelines that we have planned are as follows;
The evaluation is expected to start during March 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during April 2022. The deadline for submissions is expected in approximately mid-June 2022.
We will be in touch shortly to confirm the status of the review consideration for TA504; Pirfenidone for treating idiopathic pulmonary fibrosis.